ClinicalTrials.gg
CompletedNCT04046484Updated May 12, 2025

PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients

A Phase 2 interventional study of Normal Saline along with standard treatment and PMZ-1620 along with standard treatment in Acute Stroke and Cerebral Ischemia, sponsored by Pharmazz, Inc.. Completed at 7 sites in India. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-05-12.

Sponsored by Pharmazz, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Jan 2018, registered Jul 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies in Stroke with a site in India — 6 open to participants now, 9 under way, 4 of them phase 3. Stroke · India.

Enrollment
52nd of 63
40 · median 317
Started
2018
with 3 others
Phase 2
7 of 70
none open now
Registered
53rd of 70
by date
Lead sponsor
3 of 70
Pharmazz, Inc.

Among the 70 studies in Stroke with a site in India, this one is the 52nd largest by enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2018, is one of 7 in phase 2, and was the 53rd registered.

Stroke

8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

Browse Stroke studies →

Open to participants now

6 of the 70 studies in Stroke with a site in India are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 1,419 Stroke studies recruiting now, 695 (49%) set no upper age limit and 283 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Stroke with a site in India, or all of them as a file.
02

Study summary

This was a prospective, multicentric, randomized, double blind, parallel, saline controlled Phase II clinical study to compare the safety and efficacy of PMZ-1620 (INN: Sovateltide) therapy along with standard supportive care in patients of acute ischemic stroke.

Read the detailed description

There are hidden stem cells in the brain, which becomes active following injury to the brain. Intravenous administration of PMZ-1620 (sovateltide) augments the activity of neuronal progenitor cells in the brain to repair the damage by formation of new mature neurons and blood vessels. In addition, PMZ-1620 has anti-apoptotic activity and also increases cerebral blood flow when administered following ischemia.

03

Conditions studied

  • Acute Stroke
  • Cerebral Ischemia
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult males or females Aged 18 years through 70 years (have not had their 71st birthday)
  2. Signed and dated from Legally Acceptable Representative, if subject is not in the condition to give consent. However, when the subject is stable and is able to give consent, consent would be obtained on a separate informed consent form to confirm his/her willingness to continue in the study
  3. Stroke is ischemic in origin, supratentorial, and radiologically confirmed Computed Tomography (CT) scan or diagnostic magnetic resonance imaging (MRI) prior to enrolment
  4. New (first time) cerebral ischemic strokes subjects presenting upto 24 hours after onset of symptoms (mRS score of 3-4) with a prestroke mRS score of 0 or 1 and NIHSS score of 5-14)
  5. No hemorrhage as proved by cerebral CT/MRI scan
  6. Subject is \< 24 hours from time of stroke onset when the first dose of PMZ-1620 therapy is administered. Time of onset is when symptoms began; for stroke that occurred during sleep, time of onset is when subject was last seen or was self- reported to be normal
  7. Reasonable expectation of availability to receive the full PMZ-1620 course of therapy, and to be available for subsequent follow-up visits
  8. Subjects receiving thrombolytic therapy
  9. Reasonable expectation that subject will receive standard post- stroke physical, occupational, speech, and cognitive therapy as indicated
  10. Female subject is either:

    • Not of , defined as for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or,
    • If of childbearing potential, agrees to use any of the following effective separate forms of throughout the study, up to and including the follow-up visits: Condoms, sponge, foams, jellies, diaphragm or intrauterine device, OR A vasectomised partner OR abstinence

Exclusion criteria

Exclusion Criteria:

  1. Subjects receiving endovascular therapy
  2. Subjects presenting with lacunar, hemorrhagic and/or brain stem stroke
  3. Subjects classified as comatose, defined as a subject who required repeated stimulation to attend, or is obtunded and requires strong or painful stimulation to make movements (NIHSS Level of Consciousness (1A) score must be \< 2)
  4. Episode/exacerbation of congestive heart failure (CHF) from any cause in the last 6 months. (An episode of CHF is any heart failure that required a change in medication, change in diet or hospitalization)
  5. Evidence of intracranial hemorrhage (intracerebral hematoma, intraventricular hemorrhage, subarachnoid hemorrhage (SAH), epidural hemorrhage, acute or chronic subdural hematoma (SDH) on the baseline CT or MRI scan
  6. Known valvular heart disease with CHF in the last 6 months
  7. Known (or in the Investigator's clinical judgment) existence of severe aortic stenosis or mitral stenosis
  8. Cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft, (CABG), valve replacement surgery) in the last 6 months
  9. Subject is a candidate for any surgical intervention for treatment of stroke which may include but not limited to endovascular techniques
  10. Subjects who are obese, (BMI) > 30 and/or on hormonal
  11. Hypo- or hyperglycemia sufficient to account for the neurological symptoms; patient should be excluded if their blood glucose is \< 3.0 or > 20.0 mmol/L
  12. Patient has systolic BP \< 90 mmHg or > 220 mmHg or diastolic BP \< 40 mmHg or > 130 mmHg
  13. Acute myocardial infarction in the last 6 months
  14. Signs or symptoms of acute myocardial infarction, including findings, on admission
  15. Concomitant treatment with neuroprotective or nootropic drugs (e.g. piracetam, citicoline, , neuroprotecti-ve substances)
  16. Qualitative estimation of troponin on admission
  17. Suspicion of aortic dissection on admission
  18. Acute arrhythmia (including any tachy- or bradycardia) with hemodynamic instability on admission (systolic BP \< 100 mmHg)
  19. Findings on physical examination of any of the following: (1) jugular venous distention (JVP > 4 cm above the sternal angle); (2) 3rd heart sound; (3) resting tachycardia (heart rate > 100/min) attributable to CHF; (4) lower extremity pitting edema attributable to CHF; (5) bilateral rales; and/or (6) if a chest x-ray is performed, definite evidence of pulmonary edema, bilateral pleural effusion, or pulmonary vascular redistribution
  20. Current acute or chronic lung disease requiring supplemental chronic or intermittent oxygen therapy
  21. Serum creatinine > 2.0 mg/dL or 180 μmol/L
  22. Severe chronic anemia ( \< 7.5 g/dL)
  23. Pregnancy, breastfeeding or positive pregnancy test. (Women of childbearing age must have a negative pregnancy test prior to study drug administration)
  24. Concurrent participation in any other therapeutic clinical trial
  25. Evidence of any other major life-threatening or serious medical condition that would prevent completion of the study protocol, impair the assessment of outcome, or in which PMZ-1620 therapy would be or might cause harm to the subject
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Normal Saline (Dose: Equal volume) + Standard of care

    Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.

    Drug: Normal Saline along with standard treatment

  • Experimental
    PMZ-1620 + Standard of care

    Patients will receive the best available standard of care. In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).

    Drug: PMZ-1620 along with standard treatment

Interventions

  • DrugNormal Saline along with standard treatment

    The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.

    Also known as: Vehicle

  • DrugPMZ-1620 along with standard treatment

    Drug page: Sovateltide

    PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.

    Also known as: Sovateltide (IRL-1620) along with standard treatment

06

What researchers measure

Primary outcomes

  1. Incidence of PMZ-1620 related adverse events

    The primary objective of the study is to determine incidence of drug (PMZ-1620) related adverse events.

    Time frame: 90 days

  2. Number of patients not receiving full treatment

    Tolerability will be determined by the number of patients that do not receive all the 9 doses of PMZ-1620.

    Time frame: 90 days

Secondary outcomes

  1. Change in National Institute of Health Stroke Scale (NIHSS)

    To determine whether PMZ-1620 therapy over and above standard of care increases the proportion of ischemic stroke subjects with National Institute of Health Stroke Scale (NIHSS) score ≥ 6 score at 3 months. NIHSS is 42 point scale where 0 is the best o and 42 is the worst outcome.

    Time frame: 90 days

  2. Change in modified Rankin Scale (mRS)

    Neurological outcome as assessed by modified Rankin Scale (mRS) score ≤ 2 at 3 months post randomization. mRS is a 7 grade scale from 0 to 6, where 0 is the best and 6 is the worst outcome.

    Time frame: 90 days

  3. Change in Barthel index [BI]

    Overall clinical outcome as assessed by Barthel index \[BI\] scores) at 3 months post randomization. BI is a 10 item scale with scores ranging from 0 to 100, where a score of 100 is the best and 0 is the worst outcome.

    Time frame: 90 days

  4. Change in EuroQol

    Quality-of-life (QoL) as assessed by EuroQol at 3 months post randomization. European quality of life is a five dimension instrument with scores ranging from 0 to 100, where a score of 100 is the best and 0 is the worst outcome.

    Time frame: 90 days

  5. Change in Stroke-Specific Quality of Life (SSQOL)

    Stroke-Specific Quality of Life (SSQOL) at 3 months post randomization. SSQOL is composed of 49 items with scores ranging from 49 to 245, where a score of 245 is the best and 49 is the worst outcome.

    Time frame: 90 days

  6. Incidence in recurrence of ischemic stroke

    Incidence of recurrent ischemic stroke within 1 month and 3 months post randomization, as assessed by Questionnaire to Validate Stroke-Free Status (QVSFS)

    Time frame: 90 days

  7. Incidence of mortality

    Incidence of mortality within 3 months post randomization

    Time frame: 90 days

  8. Incidence of Intra-Cerebral Hemorrhage (ICH)

    Incidence of symptomatic Intra Cerebral Hemorrhage (ICH) within 24 (± 6) hours of randomization

    Time frame: 30 hours

07

Study locations

7 sites
  • Paras Hospital
    Gurgaon, 122002, India
  • Nizam's Institute of Medical Sciences
    Hyderabad, 500082, India
  • Sanjay Gandhi Post Graduate Institute of Medical Sciences
    Lucknow, 226014, India
  • Dayanand Medical College & Hospital
    Ludhiana, 141001, India
  • Department of Neurology, Christian Medical College and Hospital
    Ludhiana, 141008, India
  • New Era Hospital & Research Institute
    Nagpur, 440008, India
  • All India Institute of Medical Sciences
    New Delhi, 110029, India
08

References and documents

Publications

  • Leonard MG, Briyal S, Gulati A. Endothelin B receptor agonist, IRL-1620, provides long-term neuroprotection in cerebral ischemia in rats. Brain Res. 2012 Jun 29;1464:14-23. doi: 10.1016/j.brainres.2012.05.005. Epub 2012 May 9. PubMed 22580085 ↗
  • Leonard MG, Gulati A. Endothelin B receptor agonist, IRL-1620, enhances angiogenesis and neurogenesis following cerebral ischemia in rats. Brain Res. 2013 Aug 28;1528:28-41. doi: 10.1016/j.brainres.2013.07.002. Epub 2013 Jul 11. PubMed 23850649 ↗
  • Bhalla S, Leonard MG, Briyal S, Gulati A. Distinct Alteration in Brain Endothelin A and B Receptor Characteristics Following Focal Cerebral Ischemia in Rats. Drug Res (Stuttg). 2016 Apr;66(4):189-95. doi: 10.1055/s-0035-1559779. Epub 2015 Sep 23. PubMed 26398673 ↗
  • Briyal S, Ranjan AK, Hornick MG, Puppala AK, Luu T, Gulati A. Anti-apoptotic activity of ETB receptor agonist, IRL-1620, protects neural cells in rats with cerebral ischemia. Sci Rep. 2019 Jul 18;9(1):10439. doi: 10.1038/s41598-019-46203-x. PubMed 31320660 ↗
  • Cifuentes EG, Hornick MG, Havalad S, Donovan RL, Gulati A. Neuroprotective Effect of IRL-1620, an Endothelin B Receptor Agonist, on a Pediatric Rat Model of Middle Cerebral Artery Occlusion. Front Pediatr. 2018 Oct 23;6:310. doi: 10.3389/fped.2018.00310. eCollection 2018. PubMed 30406063 ↗
  • Gulati A, Hornick MG, Briyal S, Lavhale MS. A novel neuroregenerative approach using ET(B) receptor agonist, IRL-1620, to treat CNS disorders. Physiol Res. 2018 Jun 27;67(Suppl 1):S95-S113. doi: 10.33549/physiolres.933859. PubMed 29947531 ↗
  • Leonard MG, Briyal S, Gulati A. Endothelin B receptor agonist, IRL-1620, reduces neurological damage following permanent middle cerebral artery occlusion in rats. Brain Res. 2011 Oct 28;1420:48-58. doi: 10.1016/j.brainres.2011.08.075. Epub 2011 Sep 7. PubMed 21959172 ↗
  • Ranjan AK, Briyal S, Gulati A. Sovateltide (IRL-1620) activates neuronal differentiation and prevents mitochondrial dysfunction in adult mammalian brains following stroke. Sci Rep. 2020 Jul 29;10(1):12737. doi: 10.1038/s41598-020-69673-w. PubMed 32728189 ↗
  • Ranjan AK, Briyal S, Khandekar D, Gulati A. Sovateltide (IRL-1620) affects neuronal progenitors and prevents cerebral tissue damage after ischemic stroke. Can J Physiol Pharmacol. 2020 Sep;98(9):659-666. doi: 10.1139/cjpp-2020-0164. Epub 2020 Jun 23. PubMed 32574518 ↗
  • Gulati A, Agrawal N, Vibha D, Misra UK, Paul B, Jain D, Pandian J, Borgohain R. Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke. CNS Drugs. 2021 Jan;35(1):85-104. doi: 10.1007/s40263-020-00783-9. Epub 2021 Jan 11. PubMed 33428177 ↗

Individual participant data

Plan to share: No — Results will be communicated and published as manuscript

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Apr 2019, 14 months.

Of 132 phase 2 interventional studies under Stroke, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2019
First posted
Aug 6, 2019
StartActual
Jan 19, 2018
Primary completionActual
Apr 12, 2019
CompletionActual
Jun 30, 2019
Last update
May 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04046484
Lead sponsor
Pharmazz, Inc.
Responsible party
Sponsor
First posted
Aug 6, 2019
Start date
Jan 19, 2018
Primary completion
Apr 12, 2019
Completion
Jun 30, 2019
Last update
May 12, 2025

Study contacts

Anil Gulati
study chair · Pharmazz, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sovateltide

Start the discussion